|
|
Exchange: |
OTC Bulletin Board |
Security
Type: |
Common |
Shares
Out: |
41,560,000 |
Market
Cap: |
260.58(M) |
Last
Volume: |
5,200 |
Avg
Vol: |
5,186 |
52
Week Range: |
$3.61 - $10.69 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Health Services |
Level
III Sector: |
Medical Appliances & Equipment |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Axogen is focused on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Co.'s platform for peripheral nerve repair features a portfolio of products, including Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; and Axoguard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed peripheral nerves. Co. also provides Axotouch Two-Point Discriminator, which is used to measure the innervation density of any surface area of the skin.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
30,000 |
30,000 |
Total Buy Value |
$0 |
$0 |
$188,940 |
$188,940 |
Total People Bought |
0 |
0 |
3 |
3 |
Total Buy Transactions |
0 |
0 |
3 |
3 |
Total Shares Sold |
118,082 |
130,582 |
172,562 |
368,410 |
Total Sell Value |
$980,899 |
$1,074,708 |
$1,440,488 |
$3,484,755 |
Total People Sold |
5 |
6 |
6 |
6 |
Total Sell Transactions |
6 |
7 |
8 |
21 |
End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Martinez Maria D. |
Chief Human Resources Officer |
|
2021-07-19 |
4 |
A |
$0.00 |
$0 |
D/D |
2,572 |
5,504 |
|
- |
|
Donovan Michael Patrick |
VP Operations |
|
2021-07-19 |
4 |
A |
$0.00 |
$0 |
D/D |
2,572 |
43,411 |
|
- |
|
Sandberg Eric |
Chief Commercial Officer |
|
2021-07-19 |
4 |
A |
$0.00 |
$0 |
D/D |
4,408 |
7,631 |
|
- |
|
Freitag Gregory Gene |
Director |
|
2021-06-17 |
4 |
D |
$20.92 |
$183,699 |
D/D |
(8,781) |
355,775 |
|
- |
|
Freitag Gregory Gene |
Director |
|
2021-06-17 |
4 |
OE |
$19.17 |
$177,323 |
D/D |
9,250 |
364,556 |
|
- |
|
Martinez Maria D. |
Chief Human Resources Officer |
|
2021-06-04 |
4 |
S |
$18.86 |
$50,017 |
D/D |
(2,652) |
2,932 |
|
25% |
|
Freitag Gregory Gene |
Director |
|
2021-06-04 |
4 |
OE |
$3.67 |
$88,080 |
D/D |
24,000 |
355,306 |
|
- |
|
Blackford Quentin S. |
Director |
|
2021-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,173 |
24,299 |
|
- |
|
Wendell Amy Mcbride |
Director |
|
2021-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,173 |
32,097 |
|
- |
|
Neels Guido J |
Director |
|
2021-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,173 |
48,764 |
|
- |
|
Gold Mark Stephen |
Director |
|
2021-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,173 |
302,439 |
|
- |
|
Levine Alan M |
Director |
|
2021-06-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,173 |
8,764 |
|
- |
|
Freitag Gregory Gene |
Director |
|
2021-05-26 |
4 |
OE |
$3.67 |
$692,001 |
D/D |
102,954 |
331,306 |
|
- |
|
Neels Guido J |
Director |
|
2021-05-19 |
4 |
OE |
$3.80 |
$171,350 |
D/D |
40,000 |
42,591 |
|
- |
|
Devinney Erick Wayne |
VP of Clin. & Trans. Sciences |
|
2021-04-28 |
4 |
OE |
$2.86 |
$28,600 |
D/D |
10,000 |
78,082 |
|
- |
|
Zaderej Karen L. |
CEO |
|
2021-04-16 |
4 |
OE |
$5.09 |
$509,000 |
D/D |
100,000 |
765,912 |
|
- |
|
Zaderej Karen L. |
CEO |
|
2021-03-25 |
4 |
OE |
$3.67 |
$126,615 |
D/D |
34,500 |
665,912 |
|
- |
|
Freitag Gregory Gene |
Director |
|
2021-02-25 |
4 |
AS |
$22.06 |
$529,440 |
D/D |
(24,000) |
228,352 |
|
0% |
|
Donovan Michael Patrick |
VP Operations |
|
2021-02-18 |
4 |
AS |
$19.15 |
$34,623 |
D/D |
(1,808) |
40,839 |
|
11% |
|
Donovan Michael Patrick |
VP Operations |
|
2021-02-17 |
4 |
D |
$18.71 |
$14,912 |
D/D |
(797) |
42,647 |
|
- |
|
Freitag Gregory Gene |
Director |
|
2021-02-17 |
4 |
D |
$18.70 |
$29,490 |
D/D |
(1,577) |
252,352 |
|
- |
|
Mariani Peter J |
Chief Financial Officer |
|
2021-02-17 |
4 |
D |
$18.70 |
$55,261 |
D/D |
(2,954) |
18,234 |
|
- |
|
Zaderej Karen L. |
CEO |
|
2021-02-17 |
4 |
D |
$18.71 |
$143,805 |
D/D |
(7,686) |
631,412 |
|
- |
|
Friedman Mark Louis |
VP, Regulatory & Quality |
|
2021-02-17 |
4 |
D |
$18.70 |
$17,787 |
D/D |
(951) |
13,936 |
|
- |
|
Martinez Maria D. |
Chief Human Resources Officer |
|
2021-02-17 |
4 |
D |
$18.71 |
$7,596 |
D/D |
(406) |
5,584 |
|
- |
|
529 Records found
|
|
Page 9 of 22 |
|
|